These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22684466)

  • 1. Panobinostat shows efficacy in Hodgkin lymphoma.
    Cancer Discov; 2012 Jun; 2(6):OF8. PubMed ID: 22684466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful?
    Canellos GP
    J Clin Oncol; 2012 Jun; 30(18):2171-2. PubMed ID: 22547611
    [No Abstract]   [Full Text] [Related]  

  • 3. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
    Younes A; Sureda A; Ben-Yehuda D; Zinzani PL; Ong TC; Prince HM; Harrison SJ; Kirschbaum M; Johnston P; Gallagher J; Le Corre C; Shen A; Engert A
    J Clin Oncol; 2012 Jun; 30(18):2197-203. PubMed ID: 22547596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.
    Oki Y; Buglio D; Zhang J; Ying Y; Zhou S; Sureda A; Ben-Yehuda D; Zinzani PL; Prince HM; Harrison SJ; Kirschbaum M; Johnston PB; Shen A; von Tresckow B; Younes A
    Blood Cancer J; 2014 Aug; 4(8):e236. PubMed ID: 25105535
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase I study of panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):5-6. PubMed ID: 24870872
    [No Abstract]   [Full Text] [Related]  

  • 6. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.
    Oki Y; Copeland A; Hagemeister F; Fayad LE; Fanale M; Romaguera J; Younes A
    Blood; 2012 Mar; 119(9):2171-2. PubMed ID: 22383790
    [No Abstract]   [Full Text] [Related]  

  • 7. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
    Dickinson M; Ritchie D; DeAngelo DJ; Spencer A; Ottmann OG; Fischer T; Bhalla KN; Liu A; Parker K; Scott JW; Bishton M; Prince HM
    Br J Haematol; 2009 Oct; 147(1):97-101. PubMed ID: 19663825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of high-dose chemotherapy with hematopoietic stem cell transplantation for malignant lymphoma].
    Okamoto M
    Rinsho Ketsueki; 2001 Apr; 42(4):299-306. PubMed ID: 11400301
    [No Abstract]   [Full Text] [Related]  

  • 10. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
    Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
    Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of relapsed Hodgkin lymphoma after autologous stem cell transplantation].
    Illés Á; Simon Z; Udvardy M; Magyari F; Jóna Á; Miltényi Z
    Orv Hetil; 2017 Aug; 158(34):1338-1345. PubMed ID: 28823212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.
    Barnes JA; Redd R; Fisher DC; Hochberg EP; Takvorian T; Neuberg D; Jacobsen E; Abramson JS
    Hematol Oncol; 2018 Oct; 36(4):633-637. PubMed ID: 29956350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
    Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity.
    Chan TS; Luk TH; Lau JS; Khong PL; Kwong YL
    Ann Hematol; 2017 Apr; 96(4):647-651. PubMed ID: 28138786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma.
    Kumar A; Blum KA; Fung HC; Smith MR; Foster PA; Younes A
    Br J Haematol; 2015 Mar; 168(6):902-4. PubMed ID: 25271537
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
    Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
    Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Allogeneic hematopoietic stem cell transplantation following treatment with brentuximab vedotin for refractory Hodgkin lymphoma].
    Yamane Y; Koda Y; Kohashi S; Kato J; Hashida R; Sakurai M; Toyama T; Kikuchi T; Okayama M; Kasahara H; Karigane D; Shimizu T; Okamoto S; Mori T
    Rinsho Ketsueki; 2017; 58(7):755-759. PubMed ID: 28781270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of panobinostat in classical Hodgkin's lymphoma.
    Oki Y; Copeland A; Younes A
    Expert Rev Hematol; 2011 Jun; 4(3):245-52. PubMed ID: 21668391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.